The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012

Hdl Handle:
http://hdl.handle.net/10147/558638
Title:
The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012
Authors:
Kieran, J; Bennett, K; Coghlan, M; Bergin, C; Barry, M
Citation:
Kieran, J. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012. Irish Medical Journal. Vol.108 No.5 2015.
Publisher:
Irish Medical Journal
Journal:
Irish Medical Journal
Issue Date:
Jun-2015
URI:
http://hdl.handle.net/10147/558638
Abstract:
Chronic Hepatitis C (HCV) is estimated to infect 20,000 to 50,000 people in Ireland. National estimates of the number of patients who have been treated for HCV, their demographics and the cost associated with that treatment have not been published. Prescriptions for the treatment of HCV from 2000-2012 were established by interrogating the records of the High-Tech Drug Scheme and the pharmacy records of the Genitourinary Medicine and Infectious Diseases department of St. James Hospital. 2320 patients were initiated on treatment for HCV. Over 27 million was spent on HCV treatment. 25.5 million was spent on anti-viral therapy and 2 million was spent on haematological growth factor support for the management of adverse effects. The budget impact of HCV treatment has been significant in Ireland. New agents for HCV will have a greater budget impact but should require less spend on adverse event management.
Item Type:
Article
Language:
en
Keywords:
HEPATITIS C; CHRONIC DISEASE

Full metadata record

DC FieldValue Language
dc.contributor.authorKieran, Jen
dc.contributor.authorBennett, Ken
dc.contributor.authorCoghlan, Men
dc.contributor.authorBergin, Cen
dc.contributor.authorBarry, Men
dc.date.accessioned2015-06-29T14:41:37Zen
dc.date.available2015-06-29T14:41:37Zen
dc.date.issued2015-06en
dc.identifier.citationKieran, J. The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012. Irish Medical Journal. Vol.108 No.5 2015.en
dc.identifier.urihttp://hdl.handle.net/10147/558638en
dc.description.abstractChronic Hepatitis C (HCV) is estimated to infect 20,000 to 50,000 people in Ireland. National estimates of the number of patients who have been treated for HCV, their demographics and the cost associated with that treatment have not been published. Prescriptions for the treatment of HCV from 2000-2012 were established by interrogating the records of the High-Tech Drug Scheme and the pharmacy records of the Genitourinary Medicine and Infectious Diseases department of St. James Hospital. 2320 patients were initiated on treatment for HCV. Over 27 million was spent on HCV treatment. 25.5 million was spent on anti-viral therapy and 2 million was spent on haematological growth factor support for the management of adverse effects. The budget impact of HCV treatment has been significant in Ireland. New agents for HCV will have a greater budget impact but should require less spend on adverse event management.en
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.subjectHEPATITIS Cen
dc.subjectCHRONIC DISEASEen
dc.titleThe Budget Impact of Hepatitis C Treatment in Ireland 2001-2012en
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.